These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 22882335

  • 1. Liver-kidney recipients with chronic viral hepatitis C treated with interferon-alpha.
    Hassan Q, Roche B, Buffet C, Bessede T, Samuel D, Charpentier B, Durrbach A.
    Transpl Int; 2012 Sep; 25(9):941-7. PubMed ID: 22882335
    [Abstract] [Full Text] [Related]

  • 2. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK, Bansal SB, Gupta A, Gulati S, Kumar A, Prasad N.
    Clin Transplant; 2006 Sep; 20(6):677-83. PubMed ID: 17100715
    [Abstract] [Full Text] [Related]

  • 3. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation.
    Bizollon T, Palazzo U, Ducerf C, Chevallier M, Elliott M, Baulieux J, Pouyet M, Trepo C.
    Hepatology; 1997 Aug; 26(2):500-4. PubMed ID: 9252166
    [Abstract] [Full Text] [Related]

  • 4. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
    Abdelmalek MF, Firpi RJ, Soldevila-Pico C, Reed AI, Hemming AW, Liu C, Crawford JM, Davis GL, Nelson DR.
    Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Antiviral therapy for hepatitis C virus recurrence following liver transplantation: long-term results from a single center experience.
    Burra P, Targhetta S, Pevere S, Boninsegna S, Guido M, Canova D, Brolese A, Masier A, D'Aloiso C, Germani G, Tomat S, Fagiuoli S.
    Transplant Proc; 2006 May; 38(4):1127-30. PubMed ID: 16757285
    [Abstract] [Full Text] [Related]

  • 8. Outcomes of acute rejection after interferon therapy in liver transplant recipients.
    Saab S, Kalmaz D, Gajjar NA, Hiatt J, Durazo F, Han S, Farmer DG, Ghobrial RM, Yersiz H, Goldstein LI, Lassman CR, Busuttil RW.
    Liver Transpl; 2004 Jul; 10(7):859-67. PubMed ID: 15237369
    [Abstract] [Full Text] [Related]

  • 9. Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12.
    Raziorrouh B, Jung MC, Schirren CA, Loehe F, Thiel M, Nitschko H, Diepolder H, Ulsenheimer A, Heeg M, Zachoval R, Gruener NH.
    Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):778-83. PubMed ID: 18617783
    [Abstract] [Full Text] [Related]

  • 10. Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin.
    Gopal DV, Rabkin JM, Berk BS, Corless CL, Chou S, Olyaei A, Orloff SL, Rosen HR.
    Liver Transpl; 2001 Mar; 7(3):181-90. PubMed ID: 11244158
    [Abstract] [Full Text] [Related]

  • 11. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation.
    Stravitz RT, Shiffman ML, Sanyal AJ, Luketic VA, Sterling RK, Heuman DM, Ashworth A, Mills AS, Contos M, Cotterell AH, Maluf D, Posner MP, Fisher RA.
    Liver Transpl; 2004 Jul; 10(7):850-8. PubMed ID: 15237368
    [Abstract] [Full Text] [Related]

  • 12. Recurrent hepatitis C after liver transplantation: a nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin.
    Ahmad J, Dodson SF, Demetris AJ, Fung JJ, Shakil AO.
    Liver Transpl; 2001 Oct; 7(10):863-9. PubMed ID: 11679984
    [Abstract] [Full Text] [Related]

  • 13. The clinical and immunologic impact of using interferon and ribavirin in the immunosuppressed host.
    Braun M, Vierling JM.
    Liver Transpl; 2003 Nov; 9(11):S79-89. PubMed ID: 14586901
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Evaluation of interleukin-8 in hepatitis C virus infection: relation to combined peg-interferon ribavirin response and genotype 4.
    El Sayed ZM, Mansour FA, Ghal MF, Abou-Zahra SB.
    Immunol Invest; 2011 Nov; 40(1):29-38. PubMed ID: 20809700
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Incidence, risk factors, and outcome of chronic rejection during antiviral therapy for posttransplant recurrent hepatitis C.
    Fernández I, Ulloa E, Colina F, Abradelo M, Jiménez C, Gimeno A, Meneu JC, Lumbreras C, Solís-Herruzo JA, Moreno E.
    Liver Transpl; 2009 Aug; 15(8):948-55. PubMed ID: 19642125
    [Abstract] [Full Text] [Related]

  • 18. Acute allograft rejection following interferon therapy for hepatitis C in recipients who have returned to dialysis after kidney transplant failure: case study.
    Fabrizi F, D'Ambrosio R, Pallotti F, Berardinelli L, Messa P, Martin P, Aghemo A.
    Int J Artif Organs; 2014 Nov; 37(11):803-8. PubMed ID: 25362901
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.